Time to progression ratio: promising new metric or just another metric?

Por An, Ming-Wen, Mandrekar, Sumithra J.
Publicado no Ann Transl Med (2016)

Genomic advances and their impact on clinical trial design

Por Mandrekar, Sumithra J, Sargent, Daniel J
Publicado em 2009

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

Por Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado em 2009

Biostatistics: A toolkit for exploration, validation and interpretation of clinical data

Por Mandrekar, Jayawant N., Mandrekar, Sumithra J.
Publicado em 2009

Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

Por Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado em 2009

Randomized Phase II Trials: Time for a New Era in Clinical Trial Design

Por Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado em 2010

All-Comers versus Enrichment Design Strategy in Phase II Trials

Por Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado em 2011

Systematic Reviews and Meta Analysis of Published Studies: An overview and Best Practices

Por Mandrekar, Jayawant N., Mandrekar, Sumithra J.
Publicado em 2011

Design of clinical trials for biomarker research in oncology

Por Mandrekar, Sumithra J, Sargent, Daniel J
Publicado em 2011

Predictive biomarker validation in practice: lessons from real trials

Por Mandrekar, Sumithra J, Sargent, Daniel J
Publicado em 2010

Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine

Por Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado no Chin Clin Oncol (2014)

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

Por Yan, Fangrong, Mandrekar, Sumithra J., Yuan, Ying
Publicado no Clin Cancer Res (2017)

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges

Por Mandrekar, Sumithra J., Qin, Rui, Sargent, Daniel J.
Publicado em 2010

A two-stage phase II design with direct assignment option in stage II for initial marker validation

Por An, Ming-Wen, Mandrekar, Sumithra J., Sargent, Daniel J.
Publicado em 2012

A Review of Phase II Trial Designs for Initial Marker Validation

Por Mandrekar, Sumithra J., An, Ming-Wen, Sargent, Daniel J.
Publicado em 2013

Molecular and clinical implementations of ovarian cancer mouse avatar models

Por Zayed, Amira A., Mandrekar, Sumithra J., Haluska, Paul
Publicado no Chin Clin Oncol (2015)

Precision Oncology: A New Era of Cancer Clinical Trials

Por Renfro, Lindsay A., An, Ming-Wen, Mandrekar, Sumithra J.
Publicado no Cancer Lett (2016)

The Direct Assignment Option as a Modular Design Component: An Example for the Setting of Two Predefined Subgroups

Por An, Ming-Wen, Lu, Xin, Sargent, Daniel J., Mandrekar, Sumithra J.
Publicado no Comput Math Methods Med (2015)

Repeated measures dose-finding design with time trend detection in the presence of correlated toxicity data

Por Yin, Jun, Paoletti, Xavier, Sargent, Daniel J, Mandrekar, Sumithra J
Publicado no Clin Trials (2017)

An Adaptive Multi-Stage Phase I Dose-finding Design Incorporating Continuous Efficacy and Toxicity Data from Multiple Treatment Cycles

Por Du, Yu, Yin, Jun, Sargent, Daniel J., Mandrekar, Sumithra J.
Publicado no J Biopharm Stat (2018)